Upregulation of MMP is Mediated by MEK1 Activation During Differentiation of Monocyte into Macrophage

  • Lim, Jae-Won (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Cho, Yoon-Jung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Lee, Dong-Hyun (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Jung, Byung-Chul (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kang, Han-Sol (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Tack-Joong (Division of Biological Science and Technology, College of Science and Technology, Yonsei University) ;
  • Rhee, Ki-Jong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Tae-Ue (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Yoon-Suk (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
  • Received : 2012.05.30
  • Accepted : 2012.06.08
  • Published : 2012.06.30

Abstract

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases which degrade extracellular matrix (ECM) during embryogenesis, wound healing, and tissue remodeling. Dysregulation of MMP activity is also associated with various pathological inflammatory conditions. In this study, we examined the expression pattern of MMPs during PMA-induced differentiation of THP-1 monocytic cells into macrophages. We found that MMP1, MMP8, MMP3, MMP10, MMP12, MMP19, MMP9, and MMP7 were upregulated during differentiation whereas MMP2 remained unchanged. Expression of MMPs increased in a time-dependent manner; MMP1, MMP8, MMP3, MMP10, and MMP12 increased beginning at 60 hr post PMA treatment whereas MMP19, MMP9, and MMP7 increased beginning at 24 hr post PMA treatment. To identify signal transduction pathways involved in PMA-induced upregulation of MMPs, we treated PMA-differentiated THP-1 cells with specific inhibitors for PKC, MEK1, NF-${\kappa}B$, PI3K, p38 MAPK and PLC. We found that inhibition of the MEK1 pathway blocked PMA-induced upregulation of all MMPs to varying degrees except for MMP-2. In addition, expression of select MMPs was inhibited by PI3K, p38 MAPK and PLC inhibitors. In conclusion, we show that of the MMPs examined, most MMPs were up-regulated during differentiation of monocyte into macrophage via the MEK1 pathway. These results provide basic information for studying MMPs expression during macrophage differentiation.

Acknowledgement

Supported by : 한국연구재단

References

  1. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol. 1998. 152: 199-207.
  2. Andrea S, Ulrike K, Michaela K, Johannes D, Sonja F, Jelena A. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer. 2010. 10: 553-564. https://doi.org/10.1186/1471-2407-10-553
  3. Andrew CN. Metalloproteinases expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008. 28: 2108-2114. https://doi.org/10.1161/ATVBAHA.108.173898
  4. Ardans JA, Economou AP, Martinson JM, Zhou M, Wahl LM. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol. 2002. 71: 1012-1018.
  5. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, Bourgoin P, Edwards DR, Yong VW. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003. 126: 2738-2749. https://doi.org/10.1093/brain/awg285
  6. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002. 3: 207-212. https://doi.org/10.1038/nrm763
  7. Deryugina EL, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006. 25: 9-34. https://doi.org/10.1007/s10555-006-7886-9
  8. Egeblad M, Werb Z. New functions for the matrix metallopro-teinases in cancer progression. Nat Rev Cancer. 2002. 2: 161-174. https://doi.org/10.1038/nrc745
  9. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010. 1803: 3-19. https://doi.org/10.1016/j.bbamcr.2009.07.004
  10. Feinberg MW, Jain MK, Werner F, Sibinga NES, Wiesel P, Wang H, Topper JN, Perrella MA, Lee ME. Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem. 2000. 275: 25766-25773. https://doi.org/10.1074/jbc.M002664200
  11. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer. 2003. 89: 1817-1821. https://doi.org/10.1038/sj.bjc.6601327
  12. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis. 1991. 87: 87-90. https://doi.org/10.1016/0021-9150(91)90235-U
  13. Magnus B, Daniel FJK, Stefan A. Matrix metalloproteinases in atherosclerosis. Progress i Cardiovascular Diseases. 2010. 52: 410-428. https://doi.org/10.1016/j.pcad.2009.12.002
  14. Matias-Roman S, Galvez BG, Genis L, Yanez-Mo M, de la Rosa G, Sanchez-Mateos P, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood. 2005. 105: 3956-3964. https://doi.org/10.1182/blood-2004-06-2382
  15. Moreno MJ, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994. 90: 775-778. https://doi.org/10.1161/01.CIR.90.2.775
  16. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006. 69: 562-573. https://doi.org/10.1016/j.cardiores.2005.12.002
  17. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007. 8: 211-233.
  18. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004. 4: 617-629. https://doi.org/10.1038/nri1418
  19. Pollette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 2004. 49: 179-186. https://doi.org/10.1016/j.critrevonc.2003.10.008
  20. Santiago R, Michel K, Leszek K, Gary AR, Diane MJ. Metzincin proteases and their inhibitors: foes or friends in nervous physiology. J Neurosci. 2010. 30: 15337-15357. https://doi.org/10.1523/JNEUROSCI.3467-10.2010
  21. Schafers M, Schober O, Hermann S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. J Nucl Med. 2010. 51: 663-666. https://doi.org/10.2967/jnumed.109.065698
  22. Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P. Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999. 189: 843-853. https://doi.org/10.1084/jem.189.5.843
  23. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003. 200: 448-464. https://doi.org/10.1002/path.1400
  24. Ugalde AP, Ordonez GR, Quiros PM, Puente XS, Lopez-Otín C. Metalloproteases and the degradome. Methods Mol Biol. 2010. 622: 3-29.
  25. Van Leeuwen RL, Dekker SK, Arbiser JL, Vermeer BJ, Bruijn JA, Byers HR. Phorbol ester induced rapid attachment and spreading of melanoma cells and the role of extracellular matrix proteins. J Int du Cancer. 1994. 57: 894-900. https://doi.org/10.1002/ijc.2910570620
  26. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002. 99: 157-163. https://doi.org/10.1002/ijc.10329
  27. Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y. Matrix Metalloproteinase-9 (92 Kda Gelatinase Type-Iv Collagenase) from U937 Monoblastoid Cells - Correlation with Cellular Invasion. J Cell Sci. 1993. 104: 991-999.
  28. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest. 1990. 86: 1496-1502. https://doi.org/10.1172/JCI114867
  29. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999. 13: 781-788. https://doi.org/10.1096/fasebj.13.8.781
  30. Whatling C, Bjork H, Gredmark S, Hamsten A, Eriksson P. Effect of macrophage differentiation and exposure to mildly oxidized LDL on the proteolytic repertoire of THP-1 monocytes. J Lipid Res. 2004. 45: 1768-1776. https://doi.org/10.1194/jlr.M400195-JLR200